ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Pulsetto’s Global Impact: The Fastest-Growing Mental Wellness Device of 2024

By: Get News
Surpassing $10M in revenue, Pulsetto processed nearly 40,000 orders in 2024. The company supported close to 100,000 users in managing stress and emotional well-being, earning worldwide recognition as a leader in longevity and health optimization.

Pulsetto co-founders, Povilas Sabaliauskas and Vitalijus Majorovas

Nearly half of the global population is projected to experience a mental health disorder by age 75, according to the article posted in The Lancet Psychiatry. It shows that there is an urgent need for more effective mental wellness solutions as relying on traditional medication, and even therapy hasn’t slowed the mental health pandemic. Pulsetto, a company that helps people relieve stress through their science-based vagus nerve stimulation (VNS) device introduced an innovative technological solution to battle the pandemic. Their device helps people manage stress, sleep, avoid burnout, and improve emotional well-being. The company experienced rapid growth in 2024 and has become a leader in the electronic mental wellness industry.

Pulsetto saw remarkable growth in 2024, with gross revenue hitting $10 million. This is a 3.5x increase from the previous year and a 56x growth since the company’s launch in 2021. Over the year, 39,367 orders for devices were processed through a network of more than 70 active distributors.

“We look back at how far we have come in these 3 years and are happy to see the progress,” said Vitalijus Majorovas, health tech hacker and co-founder of Pulsetto. “Many startups raise €3-4 million or more and have an advantage right from the start. We built this company with €500,000 from Kilo Health and our own resources. This was enough for us to develop Pulsetto VNS technology and be profitable from day one. As we see many positive reviews coming regularly and people telling us how our device has helped them, we understand that the med-tech industry has to continue growing.”

Pulsetto users completed over 1.3 million stress-relief sessions in 2024, which shows that the trust in the company’s VNS technology for managing mental health has been growing steadily. Most users are from the US, Canada, Australia, the UK, and Germany.

Since 2024, the device has had API integrations that allow users to monitor heart rate and heart rate variability (HRV) in real time. It offers a more personalized approach to stress management.

Athletes often face intense pressure and high stress levels, making burnout a common challenge; as a result, many are turning to technology to enhance focus, recovery, resilience, and peak performance, which led Pulsetto to partner with Paralympic silver medalist Ryan Medrano in 2024. He used company’s device to aid recovery and focus during training for the Paris Games. As a result, Pulsetto launched a subsection on their website “For Athletes”. In 2025, the company intends to start collaborating with more professional athletes to champion their devices.

Shifting focus from sports to longevity, Pulsetto gained international attention in 2024 through its feature in the Netflix documentary Don’t Die: The Man Who Wants to Live Forever. The film, featuring health optimization pioneer Bryan Johnson, positioned Pulsetto as an important tool in the longevity movement, emphasizing its role in improving quality of life and extending health spans.

“Preventive wellness practices and longevity are rapidly becoming central to health innovation,” said Povilas Sabaliauskas, stress management expert and Pulsetto co-founder. “People often turn for help after the fact, when they get hit by anxiety or have a nervous breakdown. We have to look ahead, act proactively, and use available solutions that can get faster results to recover from stress. VNS devices have already proved how advanced, drug-free solutions can address mental health challenges and support overall well-being at the same time. I believe that by helping users manage stress, improve sleep, and enhance recovery, we’re contributing to a broader shift toward proactive, sustainable health practices.”

Pulsetto is gearing up for a pivotal year in 2025, with an emphasis on advancing clinical trials and expanding its applications in wellness and beyond. The company plans a series of medical trials that have to gather concrete data on vagus nerve stimulation’s effectiveness in dealing with issues such as sleep disorders, chronic stress, and anxiety.

“We have a clear mission for 2025–to expand the boundaries of what VNS technology can achieve,” continued Majorovas.“ We’re exploring applications in areas like blood pressure regulation, inflammation, and even PTSD treatment. We hope that big data becomes more integrated into traditionally non-tech fields like medicine, and there will be more targeted and personalized approaches on how to improve wellness, speed up recovery, and stop mental health issues before they escalate.”

ABOUT PULSETTO

Pulsetto is a company that offers a scientifically based vagus nerve stimulator designed to help users manage stress by engaging the parasympathetic nervous system. With its advanced neuromodulation technology, Pulsetto provides an easy-to-use option for those looking to support mental well-being and manage stress through wearable technology.

Media Contact
Company Name: PULSETTO
Contact Person: Povilas Sabaliauskas
Email: Send Email
Country: United States
Website: https://pulsetto.tech/

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.